The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback